Vanda Q2 2026 net loss widens to $62.5 million as product sales fall 4%
Vanda Pharmaceuticals reported second quarter 2026 total net product sales of $50.5 million, down 4% from $52.6 million a year earlier, as HETLIOZ sales fell 66% while Fanapt rose 23%. The net loss widened to $62.5 million, or $1.04 per diluted share, from $27.2 million, or $0.46, as operating expenses rose, and the company reiterated its full-year 2026 total revenue guidance of $240 million to $290 million.
Key points
- Q2 2026 total net product sales were $50.5 million, down 4% year over year; Fanapt rose 23% to $36.0 million while HETLIOZ fell 66% to $5.6 million.
- Q2 2026 net loss was $62.5 million ($1.04 per diluted share), compared with $27.2 million ($0.46) in Q2 2025.
- Approximately $7.0 million of HETLIOZ orders shipped June 29, 2026 are excluded from Q2 sales and will be recognized in Q3 2026.
- Cash, cash equivalents and marketable securities were $170.0 million at June 30, 2026, with funding expected through at least the end of 2027.
The filing
Written by AI on Nov 9, 2026, 10:08 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 05, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.